Over 50% of the chronic stroke population has persistent mobility deficits for which there is no standard of care. Due to RAS’ ability to improve outcomes and aid in neuroplasticity, using our device could help this population increase walking speed and reduced fall incidence over time (Thaut et al., 2018). A study on the relationship between walking speed and fall risk showed that each 0.1 m/s increase in walking speed was correlated to a 7% decrease in fall risk (Verghese et al., 2009). Research on the correlation between walking speed and community ambulation indicates that improving walking speed improves one’s ability to be a community ambulator (Fritz and Lusardi, 2009). The potential for this platform to increase walking speed, decrease fall risk, and reduce the rate of cognitive decline could profoundly impact patients’ quality of life by improving their physical and mental health as well as their ability to be community ambulators.
While Rhythmic Auditory Stimulation (RAS) has been studied in many indications, access to this therapy in clinical practice has been limited, as only a small number of clinicians (approximately 3,000 worldwide) are trained in the intervention. MedRhythms’ devices will digitize and scale RAS that has traditionally been provided by clinicians in order to bring millions of people the care they need. The FDA has recognized this novelty and potential to meet a high unmet need by granting Breakthrough Device designation to MedRhythms’ flagship product, MR-001 for chronic stroke walking deficits. The ability to use this device in-home and without a clinician will make this care available to the millions of chronic stroke survivors who need it and don’t currently have access to this treatment.
MedRhythms completed a feasibility study with the Boston University Neuromotor Recovery Lab. The publication about the study in the Journal of Neurorehabilitation and Neural Repair stated the following: "our findings demonstrate the targeted nature of the intervention and provide qualitative data that confirm the value that patients see in a music-based digital therapeutic. The intervention is readily accepted by individuals poststroke and has the potential to facilitate community-based rehabilitation. These findings, taken together with the growing body of work supporting rhythmic auditory stimulation for poststroke gait training, motivate further study and translation of this promising rehabilitation technology and intervention."
MedRhythms uses RAS as the backbone of our mission to improve patients’ walking ability and reduce their fall risk and it has been shown to improve functional outcomes, including gait speed, symmetry, stride length, balance, and fall risk across diagnoses. Every 0.1m/s increase in gait speed correlates with $2,000 of reduced healthcare costs. MedRhythms’ flagship product, MR-001 for chronic stroke walking deficits can be used in-home and can greatly reduce the cost-burden to the healthcare system by increasing gait speed using RAS.